Cargando…

Photodynamic Therapy with Verteporfin for Corneal Neovascularization

PURPOSE: To investigate the efficacy of photodynamic therapy (PDT) with verteporfin for the treatment of patients with corneal neovascularization. MATERIALS AND METHODS: Retrospective interventional case series of 33 eyes of 32 patients with stable corneal neovascularization who were refractory to c...

Descripción completa

Detalles Bibliográficos
Autor principal:	Al-Torbak, Abdullah A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2012
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3353665/ https://www.ncbi.nlm.nih.gov/pubmed/22623856 http://dx.doi.org/10.4103/0974-9233.95246

Ejemplares similares

Photodynamic Therapy With Verteporfin for Choroidal Neovascularization in Patients with Angioid Streaks
por: Lee, Jun Mok, et al.
Publicado: (2007)

Verteporfin photodynamic therapy combined with intravitreal triamcinolone for choroidal neovascularization due to angioid streaks
por: Pece, Alfredo, et al.
Publicado: (2010)

Ranibizumab, Verteporfin Photodynamic Therapy or Observation for the Treatment of Myopic Choroidal Neovascularization: Cost Effectiveness in the UK
por: Claxton, Lindsay, et al.
Publicado: (2014)

Five-year results of photodynamic therapy with verteporfin for Japanese patients with neovascular age-related macular degeneration
por: Tsuchihashi, Takashi, et al.
Publicado: (2013)

Comparison of Focal and Conventional Verteporfin Photodynamic Therapy for Chronic Central Serous Chorioretinopathy
por: Noh, Sung Rae, et al.
Publicado: (2019)

RANIBIZUMAB VERSUS VERTEPORFIN PHOTODYNAMIC THERAPY IN ASIAN PATIENTS WITH MYOPIC CHOROIDAL NEOVASCULARIZATION: BRILLIANCE, a 12-Month, Randomized, Double-Masked Study
por: Chen, Youxin, et al.
Publicado: (2019)

Red Upconverter Nanocrystals Functionalized with Verteporfin for Photodynamic Therapy Triggered by Upconversion
por: Miletto, Ivana, et al.
Publicado: (2022)

3-year follow-up of half-dose verteporfin photodynamic therapy for central serous chorioretinopathy with OCT-angiography detected choroidal neovascularization
por: Hu, Yu-Chen, et al.
Publicado: (2021)

Choroidal neovascularization reduced by targeted drug delivery with cationic liposome-encapsulated paclitaxel or targeted photodynamic therapy with verteporfin encapsulated in cationic liposomes
por: Gross, Nikolai, et al.
Publicado: (2013)

Combination verteporfin photodynamic therapy ranibizumab-dexamethasone in choroidal neovascularization due to age-related macular degeneration: results of a phase II randomized trial
por: Gallemore, Ron P, et al.
Publicado: (2017)

Video monitoring of neovessel occlusion induced by photodynamic therapy with verteporfin (Visudyne(®)), in the CAM model
por: Debefve, E., et al.
Publicado: (2008)

Macular sensitivity after half-dose verteporfin photodynamic therapy in central serous chorioretinopathy
por: Sanguansak, Thuss, et al.
Publicado: (2015)

A prospective study on different methods for the treatment of choroidal neovascularization. The efficacy of verteporfin photodynamic therapy, intravitreal bevacizumab and transpupillary thermotherapy in patients with neovascular age-related macular degeneration
por: Nowak, Michał S., et al.
Publicado: (2012)

Verteporfin photodynamic therapy of retinal capillary hemangioblastoma in von Hippel-Lindau disease
por: Bhattacharjee, Harsha, et al.
Publicado: (2010)

Retinal Capillary Hemangioma Treated with Verteporfin Photodynamic Therapy and Intravitreal Triamcinolone Acetonide
por: Suh, Shin Cho, et al.
Publicado: (2007)

Photoproducts of the Photodynamic Therapy Agent Verteporfin Identified via Laser Interfaced Mass Spectrometry
por: Furlan, Chris, et al.
Publicado: (2020)

Comparison of efficacy between low-fluence and half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy
por: Alkin, Zeynep, et al.
Publicado: (2014)

Long-term outcomes in half-dose verteporfin photodynamic therapy for chronic central serous retinopathy
por: Dhirani, Nadeem Ali, et al.
Publicado: (2017)

Verteporfin-Loaded Lipid Nanoparticles Improve Ovarian Cancer Photodynamic Therapy In Vitro and In Vivo
por: Michy, Thierry, et al.
Publicado: (2019)

Phase I/II study of verteporfin photodynamic therapy in locally advanced pancreatic cancer
por: Huggett, M T, et al.
Publicado: (2014)

One-year results of verteporfin therapy for subretinal neovascularization associated with type 2A parafoveal telengiectasia
por: Hussain, Nazimul, et al.
Publicado: (2007)

Photodynamic Therapy with Verteporfin for Chronic Central Serous Chorioretinopathy: A Review of Data and Efficacy
por: Iacono, Pierluigi, et al.
Publicado: (2020)

Two years follow-up outcome of verteporfin therapy for subfoveal choroidal neovascularization in pathologic myopia in Indian eyes
por: Hussain, Nazimul, et al.
Publicado: (2008)

A case of presumed choroidal metastasis from carcinoid tumor treated by photodynamic therapy with verteporfin
por: Kawakami, Setsuko, et al.
Publicado: (2013)

Comparison of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: The EVEREST II Randomized Clinical Trial
por: Lim, Tock H., et al.
Publicado: (2020)

Half-dose verteporfin photodynamic therapy for bullous variant of central serous chorioretinopathy: a case report
por: Ng, Winnie WK, et al.
Publicado: (2011)

The Noninvasive Treatment for Sentinel Lymph Node Metastasis by Photodynamic Therapy Using Phospholipid Polymer as a Nanotransporter of Verteporfin
por: Shimada, Kyosuke, et al.
Publicado: (2017)

Long-term efficacy and safety of verteporfin photodynamic therapy in combination with anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy
por: Jain, Prashant, et al.
Publicado: (2018)

Verteporfin Photodynamic Therapy Combined with Intravitreal Ranibizumab for Polypoidal Choroidal Vasculopathy Controversy Concerning Long-Term Followup
por: Fernández, Maribel, et al.
Publicado: (2012)

Corneal neovascularization and biological therapy
por: Voiculescu, OB, et al.
Publicado: (2015)

Lucentis(®) using Visudyne(®) study: determining the threshold-dose fluence of verteporfin photodynamic therapy combined with intravitreal ranibizumab for exudative macular degeneration
por: Chen, Eric, et al.
Publicado: (2010)

Improvement of Low Luminance Visual Acuity in Patients with Chronic Central Serous Chorioretinopathy after Half-Dose Verteporfin Photodynamic Therapy
por: Fujita, Kyoko, et al.
Publicado: (2020)

Verteporfin- and sodium porfimer-mediated photodynamic therapy enhances pancreatic cancer cell death without activating stromal cells in the microenvironment
por: Lu, Jingjing, et al.
Publicado: (2019)

Photodynamic Therapy Using Hippo Pathway Inhibitor Verteporfin: A Potential Dual Mechanistic Approach in Treatment of Soft Tissue Sarcomas
por: Rytlewski, Jeffrey D., et al.
Publicado: (2021)

Decrease in choroidal blood flow after half and one-third dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy
por: Kumashiro, Shun, et al.
Publicado: (2021)

Commentary: Long-term efficacy and safety of verteporfin photodynamic therapy in combination with anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy
por: Kumar, Atul, et al.
Publicado: (2018)

Combination of verteporfin-photodynamic therapy with 5-aza-2’-deoxycytidine enhances the anti-tumour immune response in triple negative breast cancer
por: Banerjee, Shramana M., et al.
Publicado: (2023)

In vitro effects of verteporfin on ocular cells
por: Ammar, David A., et al.
Publicado: (2013)

Corneal neovascularization: An enigma
por: Gupta, Pulkit, et al.
Publicado: (2013)

Anti-Cancer Activity of Verteporfin in Cholangiocarcinoma
por: Golino, Jihye L., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ifoms38j12tkmconrhfqkpo4bg